Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and Application (SAHAD)
Integration and Application Demonstration of Key Diagnosis and Treatment Technologies for Severe Acute High Altitude Disease
調査の概要
状態
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Gesang Luobu, MD
- 電話番号：8618108912487
- メール：kelsangnorbu@hotmail.com
研究場所
-
-
Tibet
-
Lhasa、Tibet、中国、850000
- Xizang Autonomous Region People's Hospital
-
コンタクト：
- li hui Yang
- 電話番号：13638992795
- メール：1640794768@qq.com
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Meeting the diagnostic criteria for severe acute mountain sickness (including high-altitude pulmonary edema [HAPE] and high-altitude cerebral edema [HACE]).
- Aged 18 to 75 years.
- Rapid ascent to an altitude above 2500 m within 72 hours prior to onset.
Exclusion Criteria:
- History of severe cardiopulmonary diseases.
- Pregnant women, patients with psychiatric disorders, inability to cooperate with treatment or follow-up, and patients with an expected survival of less than 6 months.
- Patients with malignant tumors, severe hepatic or renal insufficiency, or immune system diseases requiring immunosuppressive therapy.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし：HAPE： Calcium Channel Blocker (CCB) Group
Calcium Channel Blocker (CCB) Group: Nifedipine sustained-release tablets: 30-60 mg/day, orally in 2-3 divided doses;
|
|
|
介入なし：HAPE：Glucocorticoid Group
Dexamethasone: 8-16 mg/day, intravenous injection, tapering off after 3-5 days; Methylprednisolone: 40-80 mg/day, intravenous injection; Prednisone: 40-60 mg/day, oral administration;
|
|
|
介入なし：HAPE：Diuretic Group
Furosemide: 40-80 mg/day, administered intravenously or orally; Spironolactone: 40-80 mg/day, administered orally; Note: Strictly monitor electrolytes and renal function.
|
|
|
介入なし：HAPE：Theophylline Drugs Group
Aminophylline: 0.25-0.5g,
intravenous drip, 1-2 times a day; Doxofylline: 200mg, intravenous drip, 2 times a day;
|
|
|
介入なし：HAPE：Combined Treatment Group
CCB + Glucocorticoid: Nifedipine + Dexamethasone; Glucocorticoid + Diuretic: Dexamethasone + Furosemide; Triple Therapy: CCB + Glucocorticoid + Diuretic.
|
|
|
介入なし：HACE：Osmotic Diuretic Group
0.5-1.0
g/kg, rapid intravenous infusion, once every 6-8 hours; Hypertonic saline: 3% sodium chloride solution, 250 ml intravenous infusion.
Monitoring indicators: intracranial pressure, blood osmotic pressure, renal function.
|
|
|
介入なし：HACE：Intensive Glucocorticoid Treatment Group
High-dose dexamethasone: 16-32 mg/day, intravenously; Methylprednisolone pulse therapy: 500-1000 mg/day for 3 days, followed by dosage tapering.
Treatment course: 7-10 days with gradual dose reduction.
|
|
|
介入なし：HACE：Combined Intracranial Pressure-Reducing Treatment Group
Mannitol + Glucocorticoid: Mannitol 0.5 g/kg + Dexamethasone 16 mg/day; Hypertonic saline + Glucocorticoid: 3% NaCl + Methylprednisolone; Triple therapy: Mannitol + Glucocorticoid + Diuretic.
|
|
|
介入なし：HACE：Other Adjuvant Drug Group
Furosemide: 20-40 mg/day to reduce cerebral edema; Albumin: 25% albumin 50 ml to increase plasma colloid osmotic pressure; Sodium aescinate: 20-40 mg/day to improve vascular permeability.
|
|
|
実験的：Multicenter Study of HAPE：Traditional Classic Treatment Group
Oxygen inhalation plus CCB or aminophylline
|
Traditional treatment plus CPAP or BiPAP
Traditional treatment plus inhaled nitric oxide therapy (20-40 ppm, continuous administration for 12-24 hours)
|
|
実験的：Protocol for Proteomics and Peptidomics Study of HAPE：Control Group
40 healthy individuals who are either migrant residents or indigenous residents at high altitude.
Age, gender, and residential altitude were strictly matched.
Peripheral venous blood samples were collected during the same period.
|
40 patients clinically diagnosed with HAPE.
Peripheral venous blood samples were collected during the acute onset stage and prior to any effective intervention.
|
|
介入なし：HAPE Database
To establish a High-Altitude Pulmonary Edema (HAPE) Database (≥1000 cases) through a multicenter retrospective study.
|
|
|
介入なし：HACE Database
To establish a High-Altitude Pulmonary Edema (HACE) Database (≥400 cases) through a multicenter retrospective study.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
HAPE：Recovery
時間枠：From date of disease onset to achievement of recovery criteria ,assessed up to 36 months
|
Patients are defined as recovered only when all of the following criteria are met simultaneously: Resolution of clinical symptoms: complete relief of dyspnea (no shortness of breath at rest), disappearance of cough and expectoration, and resolution of chest tightness or chest pain. Restoration of normal physical signs: complete disappearance of lung crackles, resolution of cyanosis, and heart rate < 100 beats per minute at rest. Normalization of physiological parameters: blood oxygen saturation (SpO₂) ≥ 90% above 3500 m altitude (≥ 88% above 4000 m altitude) and normal arterial blood gas analysis (if performed). Improvement on imaging studies: clear bilateral lung fields on chest X-ray, and resolution of alveolar exudation without significant effusion on chest CT. Meeting hospital discharge criteria: stable condition for more than 48 hours, recovery of self-care ability, and no requirement for continuous oxygen therapy. |
From date of disease onset to achievement of recovery criteria ,assessed up to 36 months
|
|
HACE ：recovery
時間枠：From date of disease onset to achievement of recovery criteria ,assessed up to 36 months
|
Patients are defined as recovered only when all of the following criteria are met simultaneously: Recovery of consciousness: Glasgow Coma Score (GCS) of 15, full restoration of orientation, and no signs of impaired consciousness. Resolution of neurological symptoms: complete relief of headache, and disappearance of ataxia, nausea, vomiting, blurred vision, and other related symptoms. Normal neurological signs: disappearance of pathological reflexes, negative meningeal irritation signs, and normal cranial nerve function. Improvement on imaging: resolution of cerebral edema, no mass effect, and normal ventricular system on head CT or MRI. Meeting hospital discharge criteria: stable condition for more than 72 hours, recovery of activities of daily living, and no requirement for special monitoring. |
From date of disease onset to achievement of recovery criteria ,assessed up to 36 months
|
|
Death
時間枠：From admission to discharge, or all-cause mortality within 30 days and 90 days after discharge.
|
Death is defined as all-cause mortality occurring during hospitalization, or all-cause mortality within 30 days and 90 days after discharge.
|
From admission to discharge, or all-cause mortality within 30 days and 90 days after discharge.
|
|
Length of hospital stay
時間枠：The total duration from the first day of hospitalization to recovery and discharge, assessed up to 36 months
|
From the first day of admission to the day of discharge
|
The total duration from the first day of hospitalization to recovery and discharge, assessed up to 36 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
HAPE：Improvement
時間枠：At discharge(assessed up to 5 days)
|
Clinical symptoms improved by ≥50%, manifested as significant relief of dyspnea (no shortness of breath during mild activity), marked reduction in cough and expectoration, and alleviation of chest discomfort. Physiological indicators improved, including a decrease in heart rate by ≥20 beats per minute from baseline, an increase in blood oxygen saturation by ≥5% compared with admission, and a respiratory rate < 24 breaths per minute. Imaging examinations showed a ≥50% reduction in pulmonary exudation on chest radiograph compared with admission, or a significant reduction in lesion extent on chest CT. |
At discharge(assessed up to 5 days)
|
|
Length of ICU/CCU stay
時間枠：From date of the first day admimion in the ICU until the last day in the ICU, up to 48 weeks.
|
From the first day of admission to the day of discharge
|
From date of the first day admimion in the ICU until the last day in the ICU, up to 48 weeks.
|
|
Duration of mechanical ventilation
時間枠：From the date of the first day of mechanical ventilation until the last day of mechanical ventilation,up to 48 weeks.
|
Duration of mechanical ventilation, calculated in hours
|
From the date of the first day of mechanical ventilation until the last day of mechanical ventilation,up to 48 weeks.
|
|
Total hospitalization cost (CNY)
時間枠：At discharge(assessed up to 5 days)
|
total expenses incurred during hospitalization
|
At discharge(assessed up to 5 days)
|
|
Time to independence from oxygen therapy (days)
時間枠：At discharge(assessed up to 5 days)
|
Duration of oxygen therapy during hospitalization (days)
|
At discharge(assessed up to 5 days)
|
|
HAPE：incidence of complications
時間枠：From date of admission until the date of discharge, and within 30 days and 90 days after discharge,up to 48 weeks.
|
such as pulmonary embolism, pneumothorax, infection, etc
|
From date of admission until the date of discharge, and within 30 days and 90 days after discharge,up to 48 weeks.
|
|
HACE：improved
時間枠：At discharge(assessed up to 5 days)
|
A patient is defined as having "improved" if meeting the following core criteria: Improved consciousness: Glasgow Coma Scale (GCS) score increased by ≥3 points from admission, partial recovery of orientation, and improved response to stimuli. Improved neurological symptoms: ≥50% reduction in headache severity (VAS score), significant improvement in ataxia, and decreased nausea and vomiting. Improved physiological indicators: heart rate decreased by ≥15 beats per minute from baseline, blood oxygen saturation increased by ≥5% compared with admission, and blood pressure controlled within the normal range. |
At discharge(assessed up to 5 days)
|
|
HACE：Incidence of complications
時間枠：From date of admission until the date of discharge, and within 30 days and 90 days after discharge,up to 48 weeks.
|
such as seizures, intracranial infection, brain herniation, permanent neurological deficit
|
From date of admission until the date of discharge, and within 30 days and 90 days after discharge,up to 48 weeks.
|
|
HACE：Modified Rankin Scale (mRS) score at 90 days
時間枠：From the first day of admission to 90 days thereafter
|
specifically categorized as: 0 (no symptoms),
|
From the first day of admission to 90 days thereafter
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- ME-TBHP-25-090
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。